[go: up one dir, main page]

SG11202011541SA - Chimeric antigen receptor t cell therapy - Google Patents

Chimeric antigen receptor t cell therapy

Info

Publication number
SG11202011541SA
SG11202011541SA SG11202011541SA SG11202011541SA SG11202011541SA SG 11202011541S A SG11202011541S A SG 11202011541SA SG 11202011541S A SG11202011541S A SG 11202011541SA SG 11202011541S A SG11202011541S A SG 11202011541SA SG 11202011541S A SG11202011541S A SG 11202011541SA
Authority
SG
Singapore
Prior art keywords
antigen receptor
chimeric antigen
cell therapy
therapy
chimeric
Prior art date
Application number
SG11202011541SA
Other languages
English (en)
Inventor
Adrian I Bot
William Y Go
Yizhou Jiang
John M Rossi
Xiaodong Xue
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of SG11202011541SA publication Critical patent/SG11202011541SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
SG11202011541SA 2018-06-01 2019-06-03 Chimeric antigen receptor t cell therapy SG11202011541SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679755P 2018-06-01 2018-06-01
US201862774157P 2018-11-30 2018-11-30
PCT/US2019/035123 WO2019232510A1 (fr) 2018-06-01 2019-06-03 Thérapie par lymphocytes t porteurs de récepteurs antigéniques chimériques

Publications (1)

Publication Number Publication Date
SG11202011541SA true SG11202011541SA (en) 2020-12-30

Family

ID=68697134

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011541SA SG11202011541SA (en) 2018-06-01 2019-06-03 Chimeric antigen receptor t cell therapy

Country Status (12)

Country Link
US (1) US20200003758A1 (fr)
EP (2) EP3801572B1 (fr)
JP (3) JP7174777B2 (fr)
KR (4) KR20240170582A (fr)
CN (1) CN112512537A (fr)
AU (2) AU2019276592B2 (fr)
CA (1) CA3101856A1 (fr)
ES (1) ES2989910T3 (fr)
IL (2) IL278992B2 (fr)
SG (1) SG11202011541SA (fr)
TW (1) TWI856961B (fr)
WO (1) WO2019232510A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116917737A (zh) * 2021-01-10 2023-10-20 凯德药业股份有限公司 T细胞疗法
WO2024218318A1 (fr) 2023-04-21 2024-10-24 Charité - Universitätsmedizin Berlin Marqueurs pour prédiction de l'efficacité thérapeutique d'une cellule tique d'une cellule t

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG192010A1 (en) 2011-01-18 2013-08-30 Univ Pennsylvania Compositions and methods for treating cancer
EP2532740A1 (fr) 2011-06-11 2012-12-12 Michael Schmück Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
MX2014003176A (es) 2011-09-16 2015-08-05 Univ Pennsylvania Celulas t diseñadas mediante arn para el tratamiento de cancer.
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
MX2016010171A (es) 2014-02-04 2017-02-15 Us Health Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas.
KR20230148387A (ko) * 2015-05-28 2023-10-24 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
JP6952029B2 (ja) 2015-10-20 2021-10-20 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｔ細胞療法用のｔ細胞を調製する方法
BR112018070073A2 (pt) 2016-04-01 2019-02-12 Kite Pharma, Inc. receptores de antígeno quimérico e célula t e métodos de uso
AU2017297347B2 (en) 2016-07-12 2020-05-21 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
WO2018064205A1 (fr) 2016-09-28 2018-04-05 Kite Pharma, Inc. Molécules de liaison à l'antigène et leurs procédés d'utilisation
JP7142009B2 (ja) * 2016-12-01 2022-09-26 ブライトコブ インコーポレイテッド メディアストリーミングのためのコーディングプロファイルの最適化
MA46963A (fr) * 2016-12-03 2019-10-09 Juno Therapeutics Inc Méthodes pour déterminer le dosage de céllules car-t
US20190358262A1 (en) * 2016-12-03 2019-11-28 Juno Therapeutics, Inc. Methods for modulation of car-t cells
EP4008728A1 (fr) 2017-02-14 2022-06-08 Kite Pharma, Inc. Molécules de liaison à cd70 et leurs procédés d'utilisation
WO2018169922A2 (fr) 2017-03-13 2018-09-20 Kite Pharma, Inc. Récepteurs antigéniques chimériques pour le mélanome et leurs utilisations
TW201902493A (zh) 2017-04-03 2019-01-16 美商凱特製藥公司 使用併入最佳化多功能t細胞之嵌合受體t細胞之治療
EP3684803A1 (fr) 2017-09-22 2020-07-29 Kite Pharma, Inc. Molécules de liaison à l'antigène et procédés d'utilisation associés
CA3076099A1 (fr) 2017-09-22 2019-03-28 Kite Pharma, Inc. Lieurs pour des recepteurs d'antigene chimerique
BR112020007493A2 (pt) 2017-10-18 2020-10-27 Kite Pharma, Inc. métodos de administrar imunoterapia com receptor de antígeno quimérico
WO2019099707A1 (fr) 2017-11-16 2019-05-23 Kite Pharma, Inc Récepteurs antigéniques chimériques modifiés et procédés d'utilisation

Also Published As

Publication number Publication date
TWI856961B (zh) 2024-10-01
AU2023200909A1 (en) 2023-03-23
JP7174777B2 (ja) 2022-11-17
WO2019232510A1 (fr) 2019-12-05
EP3801572A4 (fr) 2022-03-09
KR102734592B1 (ko) 2024-11-27
EP3801572A1 (fr) 2021-04-14
JP7553529B2 (ja) 2024-09-18
KR102544086B1 (ko) 2023-06-16
TW202003021A (zh) 2020-01-16
JP2023024996A (ja) 2023-02-21
IL278992B1 (en) 2025-01-01
KR20240119173A (ko) 2024-08-06
IL278992A (en) 2021-01-31
CA3101856A1 (fr) 2019-12-05
EP4403224A3 (fr) 2024-07-31
KR20210014688A (ko) 2021-02-09
CN112512537A (zh) 2021-03-16
ES2989910T3 (es) 2024-11-28
KR20230093066A (ko) 2023-06-26
KR20240170582A (ko) 2024-12-03
EP3801572C0 (fr) 2024-07-03
AU2019276592A1 (en) 2020-12-10
IL317487A (en) 2025-02-01
AU2019276592B2 (en) 2022-11-24
US20200003758A1 (en) 2020-01-02
IL278992B2 (en) 2025-05-01
EP4403224A2 (fr) 2024-07-24
JP2024178207A (ja) 2024-12-24
JP2021525863A (ja) 2021-09-27
EP3801572B1 (fr) 2024-07-03

Similar Documents

Publication Publication Date Title
IL279063A (en) Chimeric antigen receptor T cells for cancer therapy
IL272302A (en) Chimeric antigen receptor-mediated cell targeting
EP3286225A4 (fr) Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
EP4054603A4 (fr) Thérapie par lymphocytes t à récepteur antigénique chimérique
GB201607968D0 (en) Chimeric antigen receptor
GB201504840D0 (en) Chimeric antigen receptor
GB201503742D0 (en) Chimeric antigen receptor
GB201610512D0 (en) Chimeric antigen receptor
ZA201906321B (en) Chimeric antigen receptor
EP3847195A4 (fr) Cellules de récepteur d'antigène chimérique pour le traitement d'une tumeur solide
SG11202102781UA (en) Chimeric antigen receptor
ZA202005837B (en) Cd83-binding chimeric antigen receptors
GB201807870D0 (en) A CD79-specific chimeric antigen receptor
IL287440A (en) Antigen-specific cd19-targeted car-t cells
SG11202101014XA (en) Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
GB201801831D0 (en) Chimeric receptor
IL278992A (en) Chimeric antigen receptor T cell therapy
GB201709508D0 (en) Chimeric antigen receptor
GB201807862D0 (en) Chimeric antigen receptor
GB202008688D0 (en) Chimeric antigen receptor cell
GB201519900D0 (en) Chimeric antigen receptor
HK40113618A (en) Chimeric antigen receptor t cell therapy
GB201721421D0 (en) Chimeric antigen receptor
HK40078990A (en) Chimeric antigen receptor t cell therapy
GB201815775D0 (en) Chimeric antigen receptor